Abeona’s new Form 483 is an­oth­er man­u­fac­tur­ing set­back for its rare skin con­di­tion as­set

Abeona Ther­a­peu­tics was hand­ed a Form 483 “re­lat­ed to process con­trols” for its epi­der­mol­y­sis bul­losa can­di­date in a sec­ond man­u­fac­tur­ing-re­lat­ed road­block for the pro­gram, with the biotech’s stock drop­ping by as much as 16% on Mon­day.

The biotech sub­mit­ted a re­sponse to the doc­u­ment on Fri­day, which not­ed con­cerns at the com­pa­ny’s man­u­fac­tur­ing site in Cleve­land, ac­cord­ing to a full-year earn­ings re­lease. The doc­u­ment was is­sued af­ter a two-week pre-li­cense in­spec­tion, which con­clud­ed on March 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER